🧬 ALK positive. But is it truly actionable?
In high-grade pulmonary neuroendocrine carcinomas, ALK IHC positivity may not tell the whole story.
Among 8 ALK IHC-positive cases in this study, only 2 had a confirmed ALK rearrangement, and both were detected by RNA sequencing.
🔬 IHC positive ≠ ALK rearranged
🧬 RNA sequencing identified fusions missed by DNA testing and even FISH in one case
🎯 Durable benefit from ALK-targeted therapy was seen in the molecularly confirmed DCTN1-ALK LCNEC case, with ongoing benefit beyond 16 months.
Takeaway: Don’t treat the stain. Confirm the driver.
🔓 Open Access linked here: https://t.co/7xxLaJKfdc
#JCP #LungPathology #ThoracicPathology #ALK #MolecularPathology #RNASequencing #NGS #NeuroendocrineCarcinoma #PrecisionOncology #Pathology
🫁 Terapias dirigidas en CPCNP avanzado: nuevas dianas y estrategias.
EGFR, ALK, ROS1, KRAS, BRAF, RET, HER2, MET y NTRK, junto con nuevas dianas como NRG1, MTAP y SMARCA4, amplían las opciones terapéuticas.
El reto: superar la resistencia adquirida, optimizar las secuencias de tratamiento y garantizar acceso al perfil molecular integral.
📖 @LancetRespirMed@HendriksLizza@dplanchard@MartinReck2
DOI 👉🏻 https://t.co/YLweiHw3x9
#CánCare #LungCancer #NSCLC #PrecisionOncology #ThoracicOncology
Children diagnosed with DIPG, an inoperable brain cancer, live just 9–12 months.
The Pediatric Brain Tumor Consortium brought together 16 hospitals to test new treatments. The Trump administration dismantled it, closing or pausing eight trials.
Our children deserve better.
🚨 dMMR ≠ Lynch syndrome!
A crucial distinction every oncologist should know.
A new Lancet review highlights the diagnostic pathway:
🔬 MLH1/PMS2 loss? Check BRAF V600E and/or MLH1 methylation.
🧬 MSH2/MSH6 or isolated MSH6/PMS2 loss? Consider germline testing.
🔍 Germline negative? Look for double-somatic MMR alterations.
💡 Key message: Tumour MMR deficiency is a starting point, not a hereditary cancer diagnosis.
📊 Save this diagnostic algorithm!
@oncoalert@esmo_open@myesmo@asco
#LynchSyndrome #PrecisionOncology
Full paper link in comment below ⬇️.
Coming to #ASH26? Don’t miss the Scientific Workshop on Emerging Technologies and Innovations in Diagnostic Hematology!
🗓 Fri, Dec 11, 3–6 PM
📍 MCCNO 252-254
Co-chairs: Christopher Park, Gerlinde Wernig & @SanjayPatelMD
Spatial biology, flow, molecular dx & AI.
Being anti vaccine is to take one of the great human success stories of all time and try to destroy it
As if there aren't enough real problems in the world to tackle.
How did the 3D genome architecture evolve? 🧬 Our new review @AnnualReviews by @zocean636 & Evan Trop in the group explores conserved genome folding principles, lineage-specific architectures, and how comparative genomics and #AI may connect sequence evolution to genome folding and function. https://t.co/QAdaEbrfQ2
Implications of TP53 mutations in patients with higher risk myelodysplastic syndromes (MDS) who received hypomethylating agent therapy: an analysis from the VALIDATE database of the International Consortium for MDS
https://t.co/PA9WKX6Os8
We are hiring! @PennCancer@Penn@PennMedicine is seeking Assistant Professors in Thoracic Oncology (Academic Clinician Track).
Join our team to deliver outstanding patient care, educate the next generation of oncologists, and advance excellence in lung cancer care.
https://t.co/oxRqhWRRMO
Vaccination is emerging as one of the most promising ways to protect yourself against future cognitive decline. Inoculations for shingles, RSV, pneumococcal disease, tetanus, diphtheria & the high-dose flu vaccine have all been tied to a reduced risk of dementia.
https://t.co/up1UIqEX5x
A liquid biospy informing prognosis at the diagnosis of early breast cancer?
"...epigenetic signatures of tumour cell subpopulations, such as basal-like cells, may be captured in blood and provide insight into disease biology beyond the static tissue-based prognostic window."
Complete garbage here from RFK Jr claiming Gardasil(HPV vaccine) is dangerous
In fact it's safe and SO effective it's on the way to ELIMINATING cervical cancer!
He's now Health Secretary of the United States..and he's never taken this back
Horrible man
Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics
Signal Transduction and Targeted Therapy https://t.co/YNT0FR1Vsg https://t.co/YNT0FR1Vsg
Really happy to share our new paper, now out in Nature Communications and open access.
We all know most GWAS hits sit in noncoding DNA, and one way they act is by changing how genes are spliced. But splicing is exquisitely cell-type-specific, and bulk RNA-seq averages all of that away. So we went to single cells.
Using the OneK1K cohort, 980 people with matched genotypes and single-cell RNA-seq of their blood immune cells, we mapped splicing regulation across 13 immune cell types: 3,337 independent cis-splicing QTLs, with subsets that differ by sex and by age. When we overlaid these on GWAS, the splicing signals colocalized with risk loci for 30 complex traits, and autoimmune disease, type 1 diabetes in particular, stood out.
My favourite part is a trans story: variants that act from a distance on RPS24 splicing, through the splicing cofactor IVNS1ABP and its interaction with HNRNPK. A small mechanistic chain, from variant to regulator to splicing, exactly the kind of thing single-cell data lets you see.
Together with our 2024 Nature Genetics paper, which did the same in Asian populations, they give a fuller picture of how splicing variation shapes disease risk across ancestries, and a lot of that picture is still cell-type-specific.
Congratulations to first authors Yan Liang and Yi Xia, and to Chi Tian, Yuntian Zhang, Yuhao Dong, and strong support from @drjosephpowell and Alex Hewitt.
Paper: https://t.co/GGQUDxjdNA
IHC dedifferentiated/undifferentiated endometrial carcinomas
-Loss of ARID1B, SMARCA4 or SMARCB1
-Complete loss or very focal expression of keratin, EMA, ER or PAX8 (in undifferentiated component)
-MMR deficient in 2/3 of tumors
-Wild Type p53 in 90-95% of tumors
Dr. Lee. 2026 Annual Meeting of the International Society of Gynecological Pathologists #pathology #PathX #ISGyP
A new single-cell atlas of non-small-cell #LungCancer found that standard staging alone can get a patient's risk wrong, in both directions.
A quarter of people staged as stage I were actually high risk. A small group of stage IV patients had survival as good as early stage disease.
This is exactly the point Lung Cancer Europe has long made through its Get Checked! campaign: a stage label is not the whole picture.
Full story: https://t.co/buPgFDezfw
1/ You think you're mapping transcription factor binding sites, but your assay might be lying to you.
Here's what you may miss about ATAC-seq and DNase-seq.
@DrNeilStone Where is the Kennedy family in all of this! They’re watching a legacy be destroyed. They should be the most vocal in condemning and stopping this mad man.